2.5(top 20%)
impact factor
2.4K(top 10%)
papers
44.5K(top 10%)
citations
83(top 10%)
h-index
2.6(top 20%)
impact factor
2.8K
all documents
47.4K
doc citations
117(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer TissuesClinical Breast Cancer2004573
2Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast CancerClinical Breast Cancer2009546
3The Global Breast Cancer Burden: Variations in Epidemiology and SurvivalClinical Breast Cancer2005445
4Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial DesignClinical Breast Cancer2009367
5Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with TrastuzumabClinical Breast Cancer2005325
6TAILORx: Trial Assigning Individualized Options for Treatment (Rx)Clinical Breast Cancer2006242
7Cognitive Training for Improving Executive Function in Chemotherapy-Treated Breast Cancer SurvivorsClinical Breast Cancer2013237
8Stress Management and Resilience Training (SMART) Program to Decrease Stress and Enhance Resilience Among Breast Cancer Survivors: A Pilot Randomized Clinical TrialClinical Breast Cancer2011219
9Insulin-Lowering Effects of Metformin in Women with Early Breast CancerClinical Breast Cancer2008214
10Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up ResultsClinical Breast Cancer2009194
11Classification, Treatment Strategy, and Associated Drug Resistance in Breast CancerClinical Breast Cancer2016193
12Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with TaxanesClinical Breast Cancer2007164
13Neoadjuvant Docetaxel in Breast Cancer: 3-Year Survival Results from the Aberdeen TrialClinical Breast Cancer2002155
14Molecular Mechanisms of Breast Cancer Metastases to BoneClinical Breast Cancer2005149
15Genetic Markers in Triple-Negative Breast CancerClinical Breast Cancer2018148
16Serum Interleukin 6, Plasma VEGF, Serum VEGF, and VEGF Platelet Load in Breast Cancer PatientsClinical Breast Cancer2002147
17Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor BurdenClinical Breast Cancer2007141
18Results of a Diet/Exercise Feasibility Trial to Prevent Adverse Body Composition Change in Breast Cancer Patients on Adjuvant ChemotherapyClinical Breast Cancer2008140
19Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialClinical Breast Cancer2021140
20Metastasis Suppressor Genes: Basic Biology and Potential Clinical UseClinical Breast Cancer2003139
21Incidence and Patterns of Distant Metastases for Patients With Early-Stage Breast Cancer After Breast Conservation TreatmentClinical Breast Cancer2013137
22Basal Breast Cancer Molecular Subtype Predicts for Lower Incidence of Axillary Lymph Node Metastases in Primary Breast CancerClinical Breast Cancer2008135
23Breast Cancer Chemotherapy-Related Cognitive DysfunctionClinical Breast Cancer2002134
24Metastatic Breast Cancer: The Treatment ChallengeClinical Breast Cancer2008134
25Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252Clinical Breast Cancer2005133
26The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled TrialClinical Breast Cancer2010133
27Mammalian Target of Rapamycin: A New Molecular Target for Breast CancerClinical Breast Cancer2003131
28Peripheral Neuropathy with Microtubule-Targeting Agents: Occurrence and Management ApproachClinical Breast Cancer2011130
29A Novel Approach Toward Development of a Rapid Blood Test for Breast CancerClinical Breast Cancer2003128
30CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast CancerClinical Breast Cancer2010128
31Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the OutcomeClinical Breast Cancer2013128
32Adjuvant Chemotherapy for Breast Cancer: Effects on Cerebral White Matter Seen in Diffusion Tensor ImagingClinical Breast Cancer2008127
33Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case HistoriesClinical Breast Cancer2004124
34Treatment of Metastatic Breast Cancer with Trastuzumab and Vinorelbine During PregnancyClinical Breast Cancer2005123
35E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast CancerClinical Breast Cancer2003121
36Review of Factors Influencing Women's Choice of Mastectomy Versus Breast Conserving Therapy in Early Stage Breast Cancer: A Systematic ReviewClinical Breast Cancer2018121
37Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital DatabaseClinical Breast Cancer2010119
38Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast CancerClinical Breast Cancer2011118
39Phase II Study of Trastuzumab plus Gemcitabine in Chemotherapy-Pretreated Patients with Metastatic Breast CancerClinical Breast Cancer2004117
40Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast CancerClinical Breast Cancer2014117
41Aromatase Inhibitor–Associated Arthralgia and/or Bone Pain: Frequency and Characterization in Non–Clinical Trial PatientsClinical Breast Cancer2007116
42Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and PathogenesisClinical Breast Cancer2010116
43Effects of Tai Chi Chuan on Insulin and Cytokine Levels in a Randomized Controlled Pilot Study on Breast Cancer SurvivorsClinical Breast Cancer2011116
44Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST TrialClinical Breast Cancer2012115
45Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label TrialClinical Breast Cancer2011113
46Feasibility of Quantifying the Effects of Epoetin Alfa Therapy on Cognitive Function in Women with Breast Cancer Undergoing Adjuvant or Neoadjuvant ChemotherapyClinical Breast Cancer2005110
47Internet Usage Among Women with Breast Cancer: An Exploratory StudyClinical Breast Cancer2000109
48Continuation of Trastuzumab Beyond Disease Progression Is Feasible and Safe in Patients with Metastatic Breast Cancer: A Retrospective Analysis of 80 Cases by the Hellenic Cooperative Oncology GroupClinical Breast Cancer2003105
49Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of LiteratureClinical Breast Cancer2017105
50Increased Rate of Brain Metastasis with Trastuzumab Therapy Not Associated with Impaired SurvivalClinical Breast Cancer2003104